(Corrects to remove extraneous words in first paragraph)
(Reuters) – Johnson & Johnson will not be undertaking local trials for its single-shot COVID-19 vaccine in India, the Economic Times reported on Tuesday, citing a company spokesperson.
While J&J had sought approval for conducting bridging trials in the country, the U.S.-based drugmaker said it wouldn’t have to do that now since India has scrapped that requirement, according to the report. (https://bit.ly/3h2x358)
The company is exploring how to accelerate the availability of its vaccine in India, the Economic Times said.
J&J did not immediately respond to a Reuters request for comment.
(Reporting by Juby Babu in Bengaluru; Editing by Shounak Dasgupta)
